Jasdeep Miglani, MD
Psychiatry · Manassas, VANPI 1326014853
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $763,888 of the $957,624 with a category attached, or 79.8%. Alkermes, Inc. accounts for 70.9% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $329,057, 3.0 times the $109,920 reported in 2019. Among psychiatry clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,280 payments — averaging $748.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$679K
- Teva Pharmaceuticals USA, Inc.$167K
- E.r. Squibb & Sons, L.L.C.$111K
- Johnson & Johnson$181
- Takeda Pharmaceuticals U.S.A., Inc.$130
- Travere Therapeutics, Inc.$38
- plus $16 from 1 others
What the payments were for
- Consulting fees$36,4254%
- Speaking & faculty fees$763,88880%
- Travel & lodging$128,82813%
- Food & beverage$28,0943%
- Education$3890%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 911 | $679,038 |
| Teva Pharmaceuticals USA, Inc. | 185 | $167,354 |
| E.r. Squibb & Sons, L.L.C. | 177 | $110,868 |
| Johnson & Johnson | 3 | $181 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $130 |
| Travere Therapeutics, Inc. | 1 | $38 |
| Acadia Pharmaceuticals Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$957,624 in reported general payments places this provider in the 95th percentile of 884 psychiatry providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AristadaAripiprazole Lauroxil | 143 | $470,600 |
| Invega SustennaPaliperidone Palmitate | 64 | $228,759 |
| UzedyRisperidone | 40 | $154,402 |
| Invega TrinzaPaliperidone Palmitate | 16 | $130,981 |
| LybalviOlanzapine/Samidorphan Malate | 39 | $61,829 |
| VraylarCariprazine Hcl | 22 | $30,802 |
| VivitrolNaltrexone Microspheres | 14 | $25,368 |
| Clozapine | 90 | $8,439 |
| TrintellixVortioxetine Hydrobromide | 13 | $6,160 |
| Haloperidol Decanoate | 94 | $4,838 |
| Ramelteon | 30 | $3,211 |
| Lamotrigine | 145 | $2,616 |
| Duloxetine Hcl | 115 | $2,181 |
| Naltrexone Hcl | 41 | $2,151 |
| Trazodone Hcl | 142 | $1,973 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Alkermes, Inc.Aristada, Lybalvi, Vivitrol | $679,038 | $557,797196 claims |
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $181 | $359,74080 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy | $167,354 | $154,40240 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $130 | $6,16013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 884 psychiatry providers in Virginia.
Other psychiatry in Manassas
- Niku SinghFalls Church$2.5M
- David ScheidererRoanoke$2.4M
- Kent McDanielGlen Allen$2.1M
- David SpiegelNorfolk$565K
- William YetterVirginia Beach$312K
- Anita ClaytonCharlottesville$260K
- Robert GardellaStaunton$201K
- Timothy KaneStaunton$162K
- Ralph McKenzieRoanoke$161K
- Ifeanyi OleleFairfax$100K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.